SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
DNTH

Dianthus Therapeutics, Inc. /DE/ (NASDAQ:DNTH)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$84.55-$0.28 (-0.33%)
 
Market cap
$4.76B
Insider Score
Health Score
Analyst consensus
Listed since
Jun 21, 2018
Market Cap$4.76B+104.0%
Revenue (ttm)$2.72M-11.7%
Net Income-$39.79M+68.5%
EPS-$0.71+100.9%
Shares Out56.31M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume784,842
Open$83.62
Previous Close$84.83
Day's Range$82.51 - $85.67
52-Week Range$35.84 - $117.88
Beta0.08
AnalystsBuy
Price Target$136.50(+61.44%)
Earnings DateMar 8, 2027

About DNTH

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Address
7 Times Square, New York, NY, 10036, US
Market Cap
4.76 billion
Employees
92
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$13.26M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
1 Buy0 Hold0 SellAvg target $117.88 (+35.5%)

1 firm rating DNTH in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From DNTH’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-0.33%
5 Days
-6.36%
1 Month
+8.26%
6 Months
-5.67%
1 Year
+103.98%

$DNTH stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in DNTH holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by DNTH's directors and management

Net Shares Purchased by Insiders−200k−100k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

DNTH Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New DNTH patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to DNTH from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in DNTH

XBIState Street SPDR S&P Biotech ETF$120.03M
VTIVanguard Morningstar Total Stock Market ETF$109.72M
IWMiShares Russell 2000 ETF$105.28M
VXFVanguard Extended Market ETF$52.31M
VBVanguard Morningstar Small-Cap ETF$49.02M
IWOiShares Russell 2000 Growth ETF$37.91M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from DNTH’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
62

News check: Analyst upside call and Q3 revenue beat offset insider selling and valuation concerns; mixed but slightly positive tone.

Recent Insider Activity

Buys
0
Sells
14
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

-34.0 since Aug 21
0255075100Aug 21 — Insider Score 34.0Aug 22 — Insider Score 34.0Aug 23 — Insider Score 34.0Aug 24 — Insider Score 34.0Aug 25 — Insider Score 34.0Aug 26 — Insider Score 34.0Aug 27 — Insider Score 34.0Aug 28 — Insider Score 34.0Aug 29 — Insider Score 34.0Aug 30 — Insider Score 34.0Aug 31 — Insider Score 34.0Sep 1 — Insider Score 0.0Sep 2 — Insider Score 0.0Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 22.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Aug 21Sep 12Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

IBRNiShares Neuroscience and Healthcare ETF3.98%
SBIOALPS Medical Breakthroughs ETF3.38%
TDNAT. Rowe Price Biotech ETF1.95%
PTHInvesco Dorsey Wright Healthcare Momentum ETF1.91%
LFSCF/M Emerald Life Sciences Innovation ETF1.57%
XBIState Street SPDR S&P Biotech ETF1.29%
TSEET. Rowe Price Small Cap ETF0.95%
BBCVirtus Biotech Clinical Trials ETF0.80%
TMEDT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF0.65%
GDOCGoldman Sachs Future Health Care Equity ETF0.62%
DWASInvesco Dorsey Wright SmallCap Momentum ETF0.58%
BMEDiShares Health Innovation Active ETF0.57%

Weight is the stock’s share of each fund’s holdings.